Drug Pipeline

Tegavivint Clinical Trials

Data updated daily from ClinicalTrials.gov — last refresh 2026-06-12
5
Active Studies
4
Recruiting
5
Top Sponsors
Active Studies by Phase
Phase 1/2
2
Phase 1
3
Active Trials
NCT IDTitleConditionStatus
Phase 1/2
NCT07463599 Safety and Efficacy of Tegavivint in Patients With Metastatic Colorectal Carcinoma Metastatic Colorectal Carcinoma (mCRC) Recruiting
NCT04851119 Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas… Colorectal Carcinoma Recruiting
Phase 1
NCT05755087 Tegavivint for Treating Patients With Relapsed or Refractory Large B-Cell Lymphoma Recurrent Diffuse Large B-Cell Lymphoma Activated B-Cell Type Recruiting
NCT07144254 Tegavivint With Gemcitabine in Patients With Relapsed or Refractory Osteosarcoma Osteosarcoma Recurrent Recruiting
NCT04874480 Tegavivint for the Treatment of Relapsed or Refractory Leukemia Recurrent Leukemia Active, Not Recruiting
Sponsors Running Tegavivint Trials
Children's Oncology Group (1) M.D. Anderson Cancer Center (1) Lapo Alinari (1) Emory University (1) HonorHealth Research Institute (1)
Disease Areas
Non-Hodgkin Lymphoma (2) Sarcoma (2) Pancreatic Cancer (1) Liver Cancer (1) Ovarian Cancer (1) Endometrial Cancer (1) Melanoma (1) Leukemia (1) DLBCL (1) Colorectal Cancer (1)
Get alerts when Tegavivint trials change
Status changes, date slips, and new filings — detected daily, delivered to your inbox.
Start monitoring free